🧬 Michael Basham, MBA, MS’ Post

Business development is key to turning discoveries into therapies. In 2024, deal activity has rebounded with notable strategic alliances, M&As, R&D Collabs and licensing agreements and more! 🛠️🤝𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐀𝐥𝐥𝐢𝐚𝐧𝐜𝐞𝐬 𝐚𝐧𝐝 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 Collaborations: Eli Lilly and Company - Isomorphic Labs: Partnered to leverage AI for drug discovery with $45M upfront and up to $1.7B in milestones. Boehringer Ingelheim - RiboBio: Collaborating on liver disease treatments, with Ribo eligible for up to $2 billion. Joint Ventures: Novartis - ARGOBIO: Formed a joint venture to develop RNA-based therapies with an upfront payment of $185M, potentially totaling $4.165B. Johnson & Johnson - Black Diamond Therapeutics: Established a joint venture to develop novel cancer therapies. 🔗💼𝐌𝐞𝐫𝐠𝐞𝐫𝐬 𝐚𝐧𝐝 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬 (𝐌&𝐀) Acquisitions: Gilead Sciences, led by Daniel O'Day acquired CymaBay Therapeutics for $4.3 billion to enhance its liver disease portfolio. Amgen, led by Bob Bradway acquired Iovance Biotherapeutics, Inc. Biotherapeutics for $1.9 billion to expand into cell therapy. Bristol Myers Squibb, led by Chris Boerner acquired Agenus for $1 billion to boost its oncology pipeline. Mergers: Eli Lilly and Company - MorphoSys: Merged to integrate advanced antibody technology into Lilly’s portfolio, valued at $3.2 billion. 📜𝐋𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭𝐬 In-Licensing: Sanofi - ARGOBIO: Secured RNA therapy rights with an upfront payment of $185M and potential total of $4.165B. Roche in-licensed Prothena Corporation's amyloid-based therapies to enhance its neurodegenerative disease pipeline. Out-Licensing: MOMA Therapeutics - Roche: Roche obtained rights to MOMA’s cancer platform for up to $2.066 billion, with $66M upfront. Regeneron out-licensed its PCSK9 inhibitor technology to Amgen for cardiovascular treatments. 🔬R&D Collaborations Pfizer & Arvinas: Collaborating on protein degrader therapies with a potential total deal value of $1.8 billion. Moderna & Merck: Partnered to develop mRNA-based cancer vaccines, combining Moderna’s mRNA expertise with Merck’s oncology technology. AstraZeneca & Iovance Biotherapeutics, Inc. Biotherapeutics: Joined forces to advance cell therapy for cancer, leveraging Iovance's technology. 💵Equity Investments & Venture Funding Venture Capital: bluebird bio, led by Andrew Obenshain raised substantial funds from venture capital to support its gene therapy programs. Scribe Therapeutics, led by Benjamin Oakes secured $80M in venture funding to advance its CRISPR-based gene-editing therapies. 🏦 IPO NantKwest - $700m IPO: Specializes in cell therapy and immuno-oncology, gaining attention for its innovative cancer treatments. PharmaGenix: $450M IPO - Works on advanced drug delivery systems and novel therapeutics. Athera Biotechnologies AB: $250M IPO - Specializes in developing therapies for autoimmune and inflammatory diseases.

🔥 Fierce Biotech yesterday announced their "Fierce 15" from companies breaking barriers and defining the future of the industry. Abdera Therapeutics - led by Lori Lyons-Williams emerged from stealth in 2023 with $142 million and a plan to use the power of radioactive decay to destroy cancerous tumors. Ascidian Therapeutics - led by Michael Ehlers was founded to rewrite RNA by editing and replacing human exons. They also recently announced a deal with Roche for $42 million upfront in June $1.8 billion in milestones. BigHat Biosciences - led by Mark DePristo have developed their Milliner platform, as well as partnerships with Johnson & Johnson, Merck & Co. and Amgen. Cour Pharmaceuticals Development Co., Inc. - led by John J. Puisis are focused on developing therapies to treat patients with autoimmune and inflammatory diseases. Excision BioTherapeutics - led by Daniel Dornbusch are developing CRISPR-based therapies for the treatment of viral infectious diseases. Fauna Bio - led by Ashley Zehnder are Examining highly conserved genes and pathways in other species to identify targets for human medicine. Gilgamesh Pharmaceuticals - led by jonathan sporn are a clinical stage neuroscience biotech developing innovative, best-in-class new chemical entities (NCEs) that target the root causes of neurological diseases, they also recently signed a $2B deal with AbbVie. iECURE, inc. - led by Joseph Truitt are tackling rare childhood diseases. ILiAD Biotechnologies, LLC - led by Keith Rubin are using vaccines for pertussis, also known as whooping cough. Kimer Med - led by Rick Kiessig are a New Zealand based Biotech are Developing broad-spectrum antiviral biologics. NodThera - led by Daniel Swisher are a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. OMass Therapeutics - led by Ros Deegan are focused in Orphan endocrine disorders, lupus, inflammatory bowel disease. The company also raised £100M Series B in 2022. ProFound Therapeutics - led by John Lepore were incubated within Flagship Pioneering focused in Protein drug discovery. Recludix Pharma - led by Nancy Whiting are Unlocking the potential of SH2 domain-targeted therapies with a focus in Inflammatory diseases and cancer. Recludix’s also partnered with Sanofi in a deal worth $125 million upfront and more than $1.2 billion in milestone payments. Tubulis GmbH - led by Dominik Schumacher are developing novel ADC's for cancer treatments. The German biotech also received an upfront payment of just under $23 million from BMS—with over $1 billion in potential milestones. 👏 Congrats to all those involved

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 12/17 Actuate Therapeutics, Inc. reports increased survival rates in phase 2 trial of elraglusib with GnP in metastatic pancreatic ductal adenocarcinoma 12/17 Biomea Fusion Reports Significant Reduction in HbA1c in Diabetes Patients Through 26-Week COVALENT-111 Study Using Icovamenib 12/17 Regeneron's phase 3 Trial of EYLEA HD Injection for Retinal Vein Occlusion-related Macular Edema Meets Primary Endpoint 12/17 Sanofi and Teva Pharmaceuticals' phase 2b RELIEVE UCCD study of duvakitug meets primary endpoints in ulcerative colitis and Crohn's disease patients 12/16 UCB's ORCHESTRA Study of Minzasolmin Fails to Meet Primary and Secondary Endpoints in Early Parkinson’s Disease Trials [Deals] 12/17 MilliporeSigma to Acquire HUB Organoids Holding B.V., Solidifying Position in Cell Culture Portfolio and Advancing Drug Development 12/17 Silexion Therapeutics Corp and Evonik Collaborate on Advanced siRNA Formulation, SIL-204, Targeting KRAS Mutations in Cancer Treatment 12/17 Orexo AB publ and Abera Bioscience AB collaborate to develop intranasal vaccines using AmorphOX technology and funding from CEPI 12/17 SK Biopharmaceuticals and ProEn Therapeutics collaborate to develop radiopharmaceutical candidates using ArtBody™ platform by 2027 12/17 Akamis Bio Partners with Xuanzhu Biopharmaceutical Co., Ltd. for the Licensing of Oncology Candidate NG-350A in Greater China 12/17 Gilead Sciences and Terray Therapeutics form strategic partnership for AI-driven drug discovery using tNova platform 12/16 Nona Biosciences and Candid Therapeutics Collaborate on $320M Agreement for T-cell Engagers Discovery in Autoimmune Diseases 12/16 Scailyte and Visterra Inc. collaborate to use AI in accelerating development of autoimmune disease treatments [Venture Capital] 12/17 Akamis Bio secures $60 million in Series A Prime financing and strategic partnership for NG-350A clinical trials in advanced rectal cancer 12/16 Concinnity Genetics secures £3m funding to advance gene control systems development for cell and gene therapy market [Regulatory] 12/17 EyeDNA Therapeutics' HORA-PDE6b therapy for inherited retinal dystrophy earns Rare Pediatric Disease Designation from US FDA 12/17 FDA Accepts Merck's Biologics License Application for Clesrovimab, Long-Acting Monoclonal Antibody for RSV Disease Prevention in Infants 12/17 FDA Fast Tracks Lipocine Inc.'s LPCN 1148 for Sarcopenia in Patients with Decompensated Cirrhosis View the full newsletter contents for free via the link in the comments.

Featured highlights from today's Bio-Research.AI Update: [Clinical Trials] 11/26 Axsome Therapeutics, Inc.' drug AXS-12 reduces frequency of cataplexy attacks in narcolepsy patients in phase 3 trial 11/26 Amgen's phase 2 Study Results: MariTide Leads to 20% Weight Loss and Decreases HbA1c Levels by 2.2 Points 11/25 Alector's Alzheimer's Drug AL002 Fails in phase 2 INVOKE-2 Trial, Plans 17% Workforce Reduction 11/25 IGC Pharma's phase 2 Trial Reveals Interim Data on IGC-AD1 for Treating Alzheimer's Agitation Symptoms with Favorable Safety Profile 11/25 AstraZeneca's TRUQAP Combined Therapy Shows Improved Survival in CAPItello-281 phase III Prostate Cancer Trial same day : ( ↑ NASDAQ: AZN | +1.17% ) 11/25 Genentech's phase III SKYSCRAPER-01 study of tiragolumab with Tecentriq in high PD-L1 NSCLC patients fails to meet overall survival endpoint [Deals] 11/26 Sarepta Therapeutics Signs $825M Global Licensing Agreement with Arrowhead Pharmaceuticals for Rare Genetic Diseases Program 11/26 boan biotech Inks Deal to Commercialize Denosumab Injection Products BA6101 and BA1102 in Brazil's $31.7B Pharmaceutical Market 11/26 Eisbach Bio GmbH receives $4.75M from CPRIT for clinical development of cancer drug EIS-12656 in Texas 11/26 Eisai Co., Ltd., Biogen Japan, and NCNP collaborate on APOE genetic testing for Alzheimer's disease treatment program 11/26 Roche to Acquire Poseida Therapeutics, Inc. for $1B, Deal May Rise to $1.5B with Addition of Non-Tradeable CVR 11/26 Bio Farma - Indonesia collaborates with GATES FOUNDATION to produce nOPV2 vaccines, secures IDR 1.4 trillion export contract for vaccines against polio, diphtheria, and tetanus 11/25 Gilead Sciences acquires HTI HIV assets from AELIX Therapeutics, bolstering HIV cure strategy amidst optimistic clinical trial results same day : ( ↑ NASDAQ: GILD | +0.33% ) 11/25 Empyrean Therapeutics Acquires First-in-Class TLR-2 Antagonist Molecule EMS-312 from Eos Therapeutics for Accelerated Cancer Drug Development [Venture Capital] 11/25 Kanglin Biotechnology raises $20 million for clinical development of KL003 gene therapy for beta thalassemia and sickle cell disease 11/25 Doron Therapeutics secures $11 million financing for phase 3 studies of MOTYS™ in knee osteoarthritis management 11/25 Secretome Therapeutics secures $20.4 million funding for phase 1 trials of STM-01 in heart failure and dilated cardiomyopathy cases [Regulatory] 11/26 Theratechnologies Inc. Resubmits sBLA for Tesamorelin F8 Formulation to FDA for HIV-Associated Lipodystrophy Treatment Review View the full newsletter contents for free via the link in the comments.

11/18/24 - 12/1/24 Biotech Deals Update 💉 Acadia Pharmaceuticals Inc. is in-licensing an experimental essential tremor medicine from Saniona for $28M upfront, plus up to $582M in milestones. The drug, SAN711, is a GABAa-α3 positive allosteric modulator that Acadia plans to advance to Phase 2 in '26 🩸 Idorsia Pharmaceuticals Ltd is negotiating an out-licensing deal for global rights to its blood pressure drug Tryvio with an unnamed partner. The agreement includes a $35M exclusivity fee, with undisclosed upfront, milestone, and royalty payments. The deal is expected to close by early '25, and will help extend Idorsia’s cash reserves. Tryvio received FDA approval in March for high blood pressure 🧬 Sarepta Therapeutics has partnered with Arrowhead Pharmaceuticals in a significant siRNA collaboration, paying $500M upfront and investing $325M in equity at a 35% premium. The deal includes rights to up to 13 programs, with 4 already in the clinic. Sarepta has committed up to $10B in future milestones and will make additional payments of $250M over 5 years plus $300M in milestones 🧬 Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, Inc. for $9/share in upfront cash, valuing Poseida at approximately $1B. Shareholders could receive an additional $4/share if certain therapies enter pivotal studies and are commercialized. The deal gives Roche access to Poseida's off-the-shelf CAR-T therapies, a R&D site, and 350 employees. Poseida's pipeline includes treatments for blood cancers, solid tumors, and autoimmune diseases, as well as preclinical genomic medicines. 💉 Gilead Sciences has acquired investigational HIV vaccine assets from Barcelona-based Aelix Therapeutics for an undisclosed amount. Aelix's HTI T cell immunogen vaccines, which completed a Ph 2a trial, are designed to elicit immune responses in people with HIV taking antiretroviral therapy 🧬 Novartis is acquiring gene therapy and neuroscience biotech Kate Therapeutics for $1.1B in upfront and milestone payments. KateTx’s pipeline includes preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and others 🇯🇵 Japanese drugmaker Kyowa Kirin International plc. is acquiring most of the commercial rights for Kura Oncology, Inc.'s targeted leukemia treatment, paying $330M upfront and almost $1.2B in milestones. Kyowa Kirin will own full commercial rights outside the US and share US rights with Kura, splitting responsibilities 50/50. Kura will lead US development, regulatory, and commercialization, while Kyowa Kirin will handle commercialization outside the US 🧬 23andMe has entered into a research partnership with Mirador Therapeutics, giving Mirador access to de-identified genetic and phenotypic data for use in target validation and precision medicine. Mirador, which launched with more than $400M in March, focuses on immune and inflammatory diseases For more deal updates, follow Liam Killingstad

Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. “Our agreement with Dren Bio is a promising opportunity to discover novel bispecific antibody therapies for cancer, building on our longstanding expertise in immuno-oncology science at Novartis,” said Shiva Malek, Ph.D., Global Head of Oncology for Biomedical Research at Novartis.   “We’re excited to collaborate to bring forward new therapeutic options for patients living with cancer, complementing our strategic efforts across a wide range of modalities, including targeted therapies, biologics, radioligand therapies and CAR-Ts.” “We are thrilled to establish this new collaboration with Novartis, a global leader in oncology,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio. “Combining the proven capabilities of Novartis in oncology drug development with Dren Bio’s novel platform could enable the advancement of important new therapies for patients.” Amit Mehta, Ph.D., Chief Operating Officer and Chief Business Officer of Dren Bio, added “Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform is designed to deplete various disease-causing agents and has led to a rich and diverse pipeline. This collaboration will benefit from Novartis' impressive track record of developing novel medicines and help further expand the reach of our platform.” Under the terms of the agreement, Dren Bio will receive a total upfront consideration of $150 million from Novartis, which includes a $25 million equity investment in the Company. Dren Bio is also eligible to receive up to $2.85 billion in additional cash payments upon achieving certain preclinical, clinical, regulatory, and commercial milestones, as well as tiered royalties on future net sales of any commercialized products resulting from the collaboration. Dren Bio and Novartis will collaborate to advance selected targeted myeloid engager programs in oncology through clinical candidate selection, at which point Novartis will assume full responsibility for all remaining development, manufacturing, regulatory, and commercialization activities. The agreement is subject to customary closing conditions including regulatory clearance. #Oncology #ImmunoOncology #TargetedMyeloidEngager  #Collaboration #DrenBio #Novartis #ReimagineMedicine

Reveal of OncoDxRx’s drug response prediction technology stirs up industry The reveal of a OncoDxRx-invented gene-to-drug prediction technology has sparked a debate across the industry regarding the extent to which it will compete or complement with NGS-based biomarker testing. PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) is a patient-derived, cfmRNA-based drug response prediction platform, invented and developed by OncoDxRx. Its development began several years ago, although its capabilities were only disclosed for the first time last year. The system is envisioned to quickly provide personalized drug response results for those cancer patients with progressive disease following therapies (i.e., non-responder population). According to the company, PGA is designed to have a wide range of predictive power, including drug efficacy, response, residual disease and recurrence risk. Because of its exclusive capabilities, high throughput, low cost and fast turnaround, currently there is no equivalent or anything close in the market today. “It is clear that the biomarker testing has created a tremendous benchmark you have to meet for entry into a very competitive precision oncology market,” OncoDxRx said. “But if you’re coming in with a revolutionary technology to gap-fill biomarker testing’s limitations, then there is no competition, you actually complete the puzzle, the test menu and benefit more patients.” The standard-of-care biomarker testing has faced considerable limitations: only qualify 20-30% of patients for precision therapy, costly with at least 2-week turnaround. As for PGA, OncoDxRx said that while the company sees no competition today, the company nonetheless “welcomes partnership, collaboration to quickly expand the market to benefit more cancer patients.” The PGA technology stands as a testament to OncoDxRx’s commitment to maintaining a robust and technologically advanced liquid biopsy platform. Its combination of advanced features, including patient-unique gene expression signatures, in silico gene-drug mapping analytics, and drug response prediction capabilities, underscores the company’s dedication to technological flexibility and barrier. As a key element in OncoDxRx’s pipeline strategy, PGA reflects the ongoing efforts to revolutionize and enhance the exclusiveness of its liquid biopsy arsenal. In an ever-evolving precision oncology landscape, PGA remains a symbol of OncoDxRx’s commitment to safeguarding its interests and contributing to improve patient outcome through a credible and reliable theranostic capability. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

New class of 'intramolecular bivalent glue' could transform cancer drug discovery 'Protein sandwich' could transform cancer drug discovery IBG1 degrades BRD2 and BRD4 independently of DCAF15. a, Structure of IBG1. b, BET protein degradation activity of IBG1. HEK293 cells were treated for 6 h with DMSO, E7820 (1 μM) or increasing concentrations of IBG1. BET protein was quantified by immunoblot. Data representative of n = 3 independent experiments. c, Whole-proteome changes after degrader treatment. Quantitative proteomics in KBM7 cells was performed after 6 h of treatment with DMSO, IBG1 (1 nM) or dBET6 (10 nM). log2-transformed fold change and −log10-transformed Benjamini–Hochberg adjusted one-way analysis of variance (ANOVA) P value compared with DMSO treatment. n = 3 biological replicates. d, NanoBRET kinetic degradation assay. BromoTag–HiBiT–BRD4 knock-in HEK293 cells were treated with IBG1 with or without MLN4924 (10 µM) pre-treatment for 1 h. Mean of n = 3 biological replicates. RLU, relative light units. e, NanoBRET kinetic ubiquitination assay. LgBiT-transfected HiBiT–BromoTag–BRD4 knock-in HEK293 cells were treated with IBG1 at indicated concentrations or at 10 nM following pre-treatment with JQ1, E7820 (both 10 µM) or MLN4924 (1 µM) for 1 h. Mean of n = 4 biological replicates. f, DCAF15-independent BET protein degradation. Wild-type (WT) and DCAF15-knockout (KO) HCT-116 cells were treated with increasing concentrations of IBG1 for 6 h and BET protein was quantified by immunoblot. Data representative of n = 3 independent experiments. A breakthrough class of molecular glue identified at the University of Dundee could pave the way for a new generation of drugs to target cancers and neurodegenerative diseases. Have defined a new class of so-called "intramolecular bivalent glue," which bind proteins—crucial to the cells that allow our bodies to function correctly—that would otherwise stay apart. "These findings have major implications for the entire pharmaceutical industry engaged in targeted protein degraders,". "This is particularly true for the development of drugs that target cancer, neurodegenerative diseases, and many more illnesses driven by proteins that have always been considered undruggable." "Proteins are essential for our cells to function properly, but when these do not work correctly, the body is vulnerable to disease." "The glue that we have been able to define is special because it first attaches itself to one protein in two places—not just one—and then recruits the second protein, effectively sandwiching the two proteins together." "We have only been able to identify this using our Targeted Protein Degradation technology and have identified a vulnerability that can be exploited by the design of new drugs that could potentially transform treatment for cancer patients and those with other untreatable diseases." #intramolecular #bivalentglue #cancer #drug #protein #pharmaceutical #neurodegenerative #cells

𝗨𝗻𝘃𝗲𝗹𝗹𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗻𝘁 𝗙𝘂𝗻𝗱𝗶𝗻𝗴,𝗠&𝗔 𝗮𝗻𝗱 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀- 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟰 BioNTech SE acquires Biotheus Inc. for $800M, gaining dual-targeting antibodies that may rival Merck's Keytruda in oncology. AstraZeneca invests $3.5B in the U.S. to expand R&D and manufacturing facilities by 2026. Merck licenses LM-299, a bispecific antibody from LaNova Medicines; pays $588M upfront, up to $2.7B in milestones. Novartis partners with Schrödinger, paying $150M upfront and up to $2.27B in milestones to advance drug discovery. Roche partners with Flare Therapeutics, paying $70M upfront and up to $1.8B in milestones to develop oncology drugs. Evotec receives €2B non-binding takeover proposal from Halozyme, Inc. Metsera raises $215M to develop longer-lasting GLP-1 obesity treatments after promising Phase 1 results. Alentis Therapeutics raises €181.4M to advance antibody-drug conjugates for solid tumors; plans Phase I/II trials. Trace Neuroscience raises $100M to develop RNA-binding therapy for ALS, aiming to preserve and improve muscle function. GSK partners with Vesalius Therapeutics, investing $80M to develop treatments for Parkinson's and another neurodegenerative disease. TRexBio raises $84M to advance immune system therapies. bluebird bio records first revenue from $3.1M sickle cell gene therapy Lyfgenia. Novo Nordisk's Q3 revenue grows 21% to €9.56B, boosted by 79% increase in Wegovy sales. Neurogene Inc. raises $200M ahead of Phase 1/2 data for Rett syndrome gene therapy; stock surges 44% on expectations of positive results. AlloVir announced a reverse merger with Kalaris Therapeutics; Kalaris investors to own 75% of combined company, providing $100M funding. Novo Nordisk partners with Ascendis Pharma, could pay up to $285M to develop long-acting GLP-1 and other metabolic drugs using Ascendis's technology. Moderna reports surprise $13M Q3 profit, aided by higher-than-expected COVID-19 vaccine sales; RSV vaccine sales lag at $10M versus $135M expected

The Bi-Specific Antibodies Therapy market is rapidly evolving, with major players making significant strides in innovative treatments. Here’s a quick look at the key companies shaping this market: 💉 Roche - A global leader in biotechnology, Roche continues to innovate with its cutting-edge bi-specific antibodies, driving progress in targeted cancer therapies. #Roche #TargetedTherapies 💊 Amgen - With a strong portfolio of bi-specific antibodies, Amgen is at the forefront of developing next-generation oncology treatments. #Amgen #OncologyInnovation 🌐 Sanofi - Sanofi is pioneering the way in immuno-oncology, with bi-specific antibodies designed to enhance immune system responses. #Sanofi #ImmunoOncology 🧪 Pfizer - Pfizer’s commitment to advanced bi-specific antibody research is opening new doors in personalized medicine. #Pfizer #PersonalizedMedicine 🔬 Johnson & Johnson - A key player in the bi-specific antibodies space, Johnson & Johnson is revolutionizing therapeutic approaches for complex diseases. #JohnsonAndJohnson #TherapeuticInnovation 🚀 AstraZeneca - AstraZeneca’s bi-specific antibodies are pushing the boundaries of precision medicine, targeting disease mechanisms more effectively. #AstraZeneca #PrecisionMedicine 🧫 AbbVie - AbbVie is harnessing the power of bi-specific antibodies to deliver breakthrough treatments in immunology and oncology. #AbbVie #BreakthroughTherapies 🌱 Lindis Biotech - Emerging as a strong contender, Lindis Biotech is driving forward with innovative bi-specific antibody solutions. #LindisBiotech #InnovativeTherapies 🔍 MacroGenics, Inc. - MacroGenics is dedicated to the development of bi-specific antibodies, focusing on novel approaches in immunotherapy. #MacroGenics #Immunotherapy 🌟 Genmab - Genmab’s expertise in antibody engineering positions it as a leader in developing highly specific bi-specific antibodies. #Genmab #AntibodyEngineering 🇨🇳 Alphamab Co. Ltd - Alphamab Co. Ltd is making waves in the bi-specific antibodies market with a strong pipeline of innovative therapies. #Alphamab #InnovativeBiologics 🔬 Akeso, Inc. - Akeso is advancing the bi-specific antibodies landscape with its focus on creating multi-functional therapeutics. #Akeso #MultifunctionalTherapeutics The Bi-Specific Antibodies Therapy market is set to transform the future of healthcare, offering hope to patients with complex conditions. Stay tuned as these key players continue to innovate and lead the way! #BiSpecificAntibodies #Biologics #Immunotherapy #Oncology #HealthcareInnovation #Biotech #Pharmaceuticals #MedicalResearch #LifeSciences Read Report @ https://lnkd.in/gxzieh6m